Kane Biotech Inc. KNBIF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -139.10% | 38.62% | 49.29% | 10.78% | -103.75% |
| Total Depreciation and Amortization | -71.94% | -58.26% | -48.90% | -22.65% | -15.62% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 241.72% | -65.41% | -106.48% | -89.05% | 98.80% |
| Change in Net Operating Assets | 102.44% | 211.40% | -170.50% | -34.70% | 68.84% |
| Cash from Operations | 17.96% | 53.97% | -62.79% | -28.49% | 64.76% |
| Capital Expenditure | -- | -- | 100.00% | 100.00% | 185.33% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 35.10% | 56.68% | 95.83% | -101.15% | 90.44% |
| Cash from Investing | 21.02% | 69.87% | -169.47% | 737.10% | -100.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 100.00% | 96.19% | 88.66% | 86.09% | 98.16% |
| Issuance of Common Stock | 3.67% | -- | 86.12% | -100.00% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 100.00% | 82.95% | 254.48% | 36.96% | 97.17% |
| Cash from Financing | -41.76% | -100.66% | 229.49% | -136.87% | 125.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -58.95% | -493.29% | 79.79% | -43.36% | 259.55% |